SCHEDULE: MAK Capital Discloses 6.1% Stake in ClearPoint Neuro

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 6.1% beneficial ownership stake in ClearPoint Neuro, Inc.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The Reporting Persons beneficially own 1,729,611 shares of ClearPoint Neuro, Inc.'s Common Stock.
• This ownership represents 6.1% of the total outstanding shares of Common Stock.
• The calculation is based on 28,423,308 shares outstanding as of October 27, 2025, as reported by ClearPoint Neuro, Inc. in its Form 10-Q filed on November 6, 2025.
• The Reporting Persons share both voting and dispositive power over all 1,729,611 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial 6.1% stake by an investment group suggests confidence in ClearPoint Neuro, Inc.'s value proposition, even if the investment is stated to be passive.

Positives

• A significant beneficial ownership stake of 6.1% by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman indicates a notable investment in ClearPoint Neuro, Inc.
• The investment group's certification that the stake is not for influencing control suggests a passive investment, potentially reducing concerns about immediate activist pressure.

Risks

• The certification regarding not influencing control, while generally positive, includes an exception for activities solely in connection with a nomination under Rule 14a-11, which could imply potential future engagement in director elections.

Future Outlook

Not applicable as this filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that a significant stake by an investment fund like MAK Capital in a medical device company such as ClearPoint Neuro, Inc. can signal confidence in the company's long-term prospects within the neurosurgery and advanced medical technology sector. Such investments often precede increased market attention, particularly if the investor has a history of successful engagements in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake. Could be perceived as a vote of confidence, potentially influencing market sentiment.
• Company Management: Awareness of a significant shareholder, though the filing indicates a passive investment intent.

Key Dates

Recommendation

The disclosure of a significant 6.1% stake by an investment group like MAK Capital is generally a positive signal, indicating investor confidence. However, without additional information on the company's operational performance, financial health, or strategic initiatives, a 'hold' recommendation is prudent. This filing primarily provides ownership structure information rather than a basis for a strong buy or sell decision, suggesting investors should maintain their current position while monitoring future company developments and MAK Capital's potential future actions.

Keywords

ClearPoint Neuro, MAK Capital, Michael A. Kaufman, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, medical device, neurosurgery